Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma, Inc. reports biopharmaceutical developments centered on YUPELRI® (revefenacin) inhalation solution, an FDA-approved maintenance treatment for chronic obstructive pulmonary disease. Company updates commonly address YUPELRI collaboration revenue, U.S. net sales recognized by Viatris, hospital-channel demand, brand profitability, and intellectual-property matters related to generic challenges.
Theravance news also covers portfolio changes following the Phase 3 CYPRESS study of ampreloxetine in symptomatic neurogenic orthostatic hypotension due to multiple system atrophy, including the decision to wind down that program. Recurring corporate updates include cost-reduction actions, operating expense trends, TRELEGY milestone economics reported by GSK, cash position, and governance or capital-allocation reviews.
Theravance Biopharma (NASDAQ: TBPH) will announce its fourth quarter and full year 2020 financial results on February 23, 2021, after market close. A conference call and webcast are scheduled for 5:00 p.m. ET. The company focuses on organ-selective medicines, targeting inflammation and immunology. Notably, it has developed YUPELRI®, an inhalation solution for COPD. The announcement may impact investors keen on financial performance metrics and future growth prospects.
Theravance Biopharma (NASDAQ: TBPH) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2:00 p.m. ET. The presentation will focus on the company's commitment to developing organ-selective medicines aimed at treating serious illnesses, particularly in inflammation and immunology. Investors can access the webcast on the company's website and the replay will be available for 30 days. Theravance's research includes the approved YUPELRI® inhalation solution for COPD, showcasing its focus on patient-centered drug development.
Theravance Biopharma (NASDAQ: TBPH) will webcast its presentation at the 3rd Annual Evercore ISI HEALTHCONx Conference on December 1, 2020, at 2:40 p.m. ET. The webcast can be accessed via the Investors section of their website www.theravance.com. Replay will be available for 30 days. The company specializes in organ-selective medicines, focusing on inflammation and immunology, with an aim to improve patient lives. Their notable product includes YUPELRI®, an FDA-approved treatment for chronic obstructive pulmonary disease.
Theravance Biopharma (NASDAQ: TBPH) reported Q3 2020 total revenue of $18.3 million, driven by a significant rise in YUPELRI's sales, which contributed approximately $13.0 million to the revenue. However, the company reported an operating loss of $76.6 million due to increased R&D and SG&A expenses, totaling $67.4 million and $27.5 million respectively. Cash reserves stood at $358.3 million. Despite market challenges from COVID-19, YUPELRI gained market share and brand profitability. The company also anticipates key clinical trial results in Q3 2021 for its pipeline products.
Theravance Biopharma (NASDAQ: TBPH) will announce its third quarter 2020 financial results and provide an update on November 5, 2020, after market close. The conference call will take place at 5:00 p.m. ET. The company focuses on developing organ-selective medicines and has a pipeline aimed at addressing significant patient needs, particularly in inflammation and immunology. They leverage expertise in developing lung-selective medicines like YUPELRI® for treating COPD. Interested parties can access the live call via phone or at their website.
Theravance Biopharma (NASDAQ: TBPH) announced its participation in two upcoming investor conferences. The first is the Morgan Stanley 18th Annual Global Healthcare Conference on September 14, 2020, at 1:30 p.m. ET, followed by the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 9:30 a.m. ET. Webcast presentations will be accessible on the company's website under the "Investors" section, with replays available for at least 30 days. Theravance specializes in organ-selective medicines targeting inflammation and immunology.
Theravance Biopharma (NASDAQ: TBPH) reported Q2 2020 revenue of $15.0 million, down $11.1 million year-over-year, primarily due to decreased collaboration and licensing revenue. Operating loss was $72.2 million, or $55.6 million without share-based compensation. Cash reserves stood at $438.3 million. The company noted a market share increase for YUPELRI despite COVID-19 challenges and aims for it to be cash-flow positive by year-end. Clinical programs for ampreloxetine and TD-1473 were delayed, but progress continues with new COVID-19 related candidate TD-0903.
Theravance Biopharma (NASDAQ: TBPH) announced the appointment of Deepika R. Pakianathan, Ph.D., to its Board of Directors as of July 2, 2020. Dr. Pakianathan has extensive experience in the biotechnology sector, previously serving as a Managing Member at Delphi Ventures and holding key positions at J.P. Morgan. Her expertise is expected to strengthen the board's capability to navigate the company's growth. CEO Rick E Winningham expressed confidence in Dr. Pakianathan's ability to enhance the company's strategic direction during this pivotal phase.
Theravance Biopharma (NASDAQ: TBPH) announced the first patient has been dosed in a Phase 2 study of TD-0903, a lung-selective JAK inhibitor targeting hospitalized COVID-19 patients with Acute Lung Injury (ALI). The study aims to assess the treatment's safety and clinical response in patients showing hypoxia. Following a successful Phase 1 study in healthy volunteers, the Phase 2 trial will occur across the UK and other European nations. TD-0903 is designed to inhibit the cytokine storm linked to ALI, potentially preventing progression to Acute Respiratory Distress Syndrome (ARDS).